Computer Billing Standard

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing.

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing. The theory is that by using a single format (ANSI is the American National Standards Institute) instead of any of the 400 or so different ones kicking around today that a health plan might mandate, life will be simpler for physicians, and practice costs will decline precipitously. Medical practices with annual receipts over $5 million must be ANSI-compliant by October 2002. Those under that ceiling have until October 2003.

Articles in this issue
Computer Technology Helps Radiologists Spot Overlooked Small Breast Cancers
New Awards Spotlight Courage of Cancer Survivors
Using the Body’s Anticancer Defenses to Guide and Improve Breast Cancer Treatment
Vaccine Studies Demonstrate Promise of Immunotherapy to Treat Breast Cancer and Prevent Recurrence
Children’s Art Project at M. D. Anderson Cancer Center
Settling on an Increased NCI Budget
Computer Billing Standard
Ligand Receives FDA Marketing Clearance for Bexarotene Gel
Mayo Clinic Study Shows Patients Uncertain About Cancer Risk Terms
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Commentary (Stenson): Indications for Selective Neck Dissection: When, How, and Why
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Costs of Smoking Among Active-Duty US Air Force Personnel—United States, 1997
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content
Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Roman Fabbricatore
June 26th 2025
Article

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

Roman Fabbricatore
June 26th 2025
Article

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.